Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. Shingles infection occurs when the virus reactivates decades after initial infection, and affects approximately one in three persons in the general population during their lifetime. Shingles is characterized by a localized, often severely painful cutaneous eruption that can last weeks or months, and occurs most frequently in older adults.
Shingles vaccine is licensed for adults ages 50 and older. The current recommendation, however, remains to routinely immunize adults 60 years and older with a one-time dose of shingles vaccine. The vaccine can be given to people who have already had an episode of shingles. Check with your doctor to see if the vaccine is needed or if it will be covered by individual medical insurance policies.
Source: Centers for Disease Control and Prevention
You also may be interested in...
Infographic
3/26/2019
Infographic about Shingrix, the FDA-approved vaccine to prevent shingles for healthy adults, age 50 and over
Recommended Content:
Shingles
Publication
3/22/2019
Due to continued high demand, additional instructions and guidance have been issued for Medical Treatment Facilities (MTFs) ordering Shingrix shingles vaccine.
Recommended Content:
Shingles
Report
2/1/2019
Shingrix, a recombinant zoster vaccine, was licensed in October 2017. Early post-licensure safety monitoring findings are consistent with prelicensure clinical trial data. Serious adverse events were rare, and no unexpected patterns were detected.
Recommended Content:
Shingles
Report
5/25/2018
Early monitoring indicates that vaccine provides might confuse administration procedures and storage requirements of the older Zostavax and newer Shingrix shingles vaccines.
Recommended Content:
Shingles
Report
5/18/2018
The percentage of adults aged ≥60 years who ever had the shingles vaccine increased from 6.7% in 2008 to 33.4% in 2016. Women were more likely than men to have had the shingles vaccine.
Recommended Content:
Shingles
Publication
5/10/2018
The purpose of this message is to provide disposition instructions on shipping delays for Shingrix (zoster recombinant, adjuvanted) vaccine.
Recommended Content:
Shingles
Publication
3/27/2018
Medical treatment facilities (MTFs) may now turn in soon-to-expire Zostavax shingles vaccine to potentially receive a credit on their Prime Vendor account.
Recommended Content:
Shingles
Publication
2/7/2018
Examples of proper storage, handling and reconstitution of Shingrix recombinant shingles vaccine.
Recommended Content:
Shingles
Fact Sheet
2/5/2018
This information paper describes the Herpes Zoster (Shingles) disease and vaccine to prevent it.
Recommended Content:
Shingles
Report
1/26/2018
Revised recommendations for use of shingles vaccines following the October 2017 approval of a new vaccine.
Recommended Content:
Shingles
Policy
- Identification #: N/A
- Date: 7/25/2011
- Type: Directives
- Topics:
Shingles
Showing results 1 - 11
Page 1 of 1